Comparison of <i>In Vitro</i> Anticancer Activity of Plumbagin Silver Nanoparticle and Monoclonal Antibody Labelled Plumbagin Silver Nanoparticle in SKBR3 Cell Lines by MTT Assay

Background: A combination of plumbagin with trastuzumab conjugated silver nanoparticle shows more inhibitory activity than plumbagin silver nanoparticle due to its target delivery. Aim: This study reports the effectiveness of monoclonal antibody labelled plumbagin nanoparticle over nanoparticle alone on targeting therapy against HER2-positive breast cancer cells. Methods: Plumbagin is encapsulated into silver nanoparticles, and these nanoparticles were conjugated with trastuzumab, a monoclonal antibody targeting HER2 receptors. Successful conjugation of trastuzumab is confirmed by SEM, TEM, FTIR and BCA assay. The result confirmed the successful conjugation of trastuzumab with plumbagin silver nanoparticle. Cytotoxicity of the conjugated nanoparticle was determined using MTT assay on SKBR3 cell lines and is compared with plumbagin nanoparticle. 100�g/ml of plumbagin was taken as the standard. Results: Plumbagin shows only 32 percent inhibitory growth with no damage to normal cells. By converting to silver nanoparticles and performing MTT assay, this shows an inhibitory growth of 45 per cent. Conjugated nanoparticle shows 72 percentage of inhibitory effect at a maximum concentration of 100 �g/ml. when up to 50 �g/ml of concentration, this shows a rapid increase in inhibitory effect. After this, there is a decrease in concentration. At a concentration of 20 �g/ml, it reaches IC50 value. Conclusion: These results demonstrate that conjugation with a monoclonal antibody enhances the inhibitory effect. Major Findings: The findings of this study highlight the potential of plumbagin silver nanoparticle conjugated with monoclonal antibodies as a promising approach for the treatment of HER2-positive breast cancer.

View article page

Download PDF